Today, the first domestic teriflunomide tablets developed by CGeneTech are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

Multiple sclerosis (MS) is a lifelong, chronic and progressive disease. More than 2.3 million people worldwide suffer from multiple sclerosis, and nearly 50000 patients in China. In May 2018, multiple sclerosis was included in the first list of rare diseases in China. Its etiology originates from the pathological changes of the autoimmune system, causing the damage and peeling of the nerve myelin sheath, resulting in the damage of the spinal cord, brain and optic nerve functions. The patient's nervous system disability gradually worsens, and the patient loses self-care ability, blindness and even life. Early diagnosis and treatment are required.

Teriflunomide is an immune modulator with anti-inflammatory effect. It has definite efficacy and good safety when taken for a long time. It is the first-line drug recommended by domestic and foreign guidelines for the treatment of multiple sclerosis. The telifloxamine tablets developed by CGeneTech passed the consistency evaluation with the original drugs. The marketing broke the current situation of excessive dependence on imported drugs for the treatment of multiple sclerosis. It will significantly improve the drug availability of domestic patients, ensure the continuity of drug supply, and not be affected by various overseas factors.

Dr. Yu Qiang, founder and CEO of CGeneTech, said: "In fact, rare diseases are not rare. But there is no medicine to cure, which is the unspeakable pain of patients with rare diseases. The earlier the diagnosis and treatment of multiple sclerosis are, the better the symptoms can be alleviated and the development of the disease can be delayed. Therefore, today we are glad to see that the terfloxacin tablets produced by CGeneTech are sold on the market, benefiting domestic patients and making every small group no longer give up. In the future, the company will focus on the unmet needs of China and the world Guided by clinical needs, we will develop innovative drugs with high accessibility and better efficacy to benefit patients worldwide. "

Founded in Suzhou Industrial Park in 2010, CGeneTech is committed to the R & D and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R & D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as glucose lowering, anticancer and rare diseases. Among them, the original hypoglycemic new drug Cetagliptin phosphate has entered the final stage of clinical phase III, which is expected to fill the gap of domestic original DPP-4 inhibitors; Three of the anticancer drugs under research have entered the clinic. The FGFR / VEGFR dual target inhibitor cgt-6321 has been carried out in phase I clinical trials in advanced solid tumors, and this drug is expected to become a potential first in class drug; CXCR4 antagonist cgt-1881 is used for hematopoietic stem cell mobilization, and oral administration is more convenient; Cgt-9475, a new generation ALK / ret inhibitor, is expected to solve several major clinical pain points such as drug resistance and brain metastasis in the treatment of lung cancer. Both of the latter two projects have obtained the clinical approval of the US FDA, which has taken a solid step in the company's innovative drugs going to sea.